Centrul De Oncologie SF Nectarie S.R.L.
- Address
- lock Available on a paid plan
Centrul De Oncologie SF Nectarie S.R.L. - Advanced Cancer Research Center
Centrul De Oncologie SF Nectarie S.R.L. is a specialized oncology research center dedicated to advancing cancer treatment through participation in cutting-edge clinical trials. The center focuses on evaluating novel immunotherapies, targeted therapies, and combination treatment regimens across multiple cancer types, with particular emphasis on immune checkpoint inhibitors and precision oncology approaches.
- Non-Small Cell Lung Cancer (NSCLC) - comprehensive research portfolio spanning early-stage adjuvant therapy, metastatic disease, and novel immunotherapy combinations including PD-1/PD-L1 inhibitors with chemotherapy
- Breast Cancer - investigating HER2-positive and hormone receptor-positive subtypes with advanced antibody-drug conjugates, targeted therapies, and combination regimens in both early and metastatic settings
- Genitourinary Malignancies - focused trials in bladder cancer, renal cell carcinoma, and prostate cancer utilizing immunotherapy, PARP inhibitors, and hormone-directed therapies
- Gastrointestinal and Hepatobiliary Cancers - clinical research in cholangiocarcinoma, gastroesophageal junction cancers, hepatocellular carcinoma, and colorectal cancer with emphasis on microsatellite instability and targeted molecular approaches
The center demonstrates extensive expertise in phase II and III clinical trials evaluating next-generation immunotherapy combinations, including nivolumab, pembrolizumab, atezolizumab, and durvalumab-based regimens. Their research portfolio encompasses innovative treatment strategies such as antibody-drug conjugates, CDK4/6 inhibitors, and PARP inhibitors across multiple solid tumor types. The center also conducts trials in melanoma, ovarian cancer, small cell lung cancer, and head and neck cancers, positioning itself as a comprehensive oncology research facility committed to advancing personalized cancer care and improving patient outcomes through participation in international multi-center studies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 208 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 206 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 41 by active trials.
lock +40 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC30trials
lock +23 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrul De Oncologie SF Nectarie S.R.L.
lock Showing 1 of 174 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 208 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 60 | Unknown | 2018-08-24 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.